Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a reviewPatrick Schöffski, Hendrik Van Poppel, Herlinde Dumez et al.|Annals of Oncology|2006Cited by 90
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaJérôme Fayette, Helena Rebelo‐de‐Andrade, Paolo Bossi et al.|Clinical Cancer Research|2025Cited by 26
Role of GRB2‐associated binder 1 in epidermal growth factor receptor‐induced signaling in head and neck squamous cell carcinomaAnn Hoeben, J. Silvio Gutkind, Daniel Martı́n et al.|International Journal of Cancer|2012Cited by 25
The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patientsAnna C. H. Willemsen, Annemie M.W.J. Schols, Nina De Moor et al.|Cancer Medicine|2022Cited by 24
Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinomaMichel Bila, Paul M. Clément, Amelie Franken et al.|Oral Oncology|2023Cited by 13